What is Mogrify?
Mogrify is a biopharmaceutical enterprise dedicated to the transformation of ex vivo cell therapies and the advancement of in vivo reprogramming technologies. The company utilizes a systematic, data-driven approach to identify the specific transcription factors required to convert one cell type into another, effectively bypassing the limitations of traditional cell therapy manufacturing. By addressing the fundamental challenges of cell identity and scalability, Mogrify is carving out a significant market position at the intersection of computational biology and clinical medicine, aiming to deliver curative treatments for a wide range of degenerative diseases.
How much funding has Mogrify raised?
Mogrify has raised a total of $47.8M across 4 funding rounds:
Angel/Seed
$3.7M
Private Equity
$1.1M
Series A
$33M
Series A
$10M
Angel/Seed (2019): $3.7M with participation from Ahren, 24Haymarket, and Dr Disley
Private Equity (2020): $1.1M led by SBRI Healthcare
Series A (2021): $33M supported by University of Bristol Enterprise Fund III, 24Haymarket, Parkwalk Advisors, Ahren Innovation Capital, Astellas Venture Management, Dr. Darrin Disley, and Dr. Jonathan Milner
Series A (2023): $10M featuring Ahren Innovation Capital, Parkwalk Advisors, and Astellas Venture Management
Key Investors in Mogrify
Ahren Innovation Capital
Ahren Innovation Capital is an investment institution focused on supporting transformational companies at the intersection of deep technology and deep science, providing both patient and active capital to empower visionary entrepreneurs.
Parkwalk Advisors
Parkwalk is a leading investor in university spinouts, focusing on deeptech innovations emerging from the UK's top universities by bridging the gap between academic research and commercial success.
Astellas Venture Management
Astellas Venture Management is the corporate venture capital organization dedicated to reinforcing Astellas Pharma Inc. through strategic investments in innovative life science ventures.
What's next for Mogrify?
With the recent influx of capital, Mogrify is well-positioned to accelerate its clinical pipeline and expand its research capabilities. The company's strategic roadmap focuses on transitioning its core platform from discovery to clinical-stage validation. By deepening its partnerships with institutional investors and leveraging its unique intellectual property, Mogrify intends to scale its manufacturing processes and broaden its therapeutic reach. The focus remains on achieving key milestones in in vivo reprogramming, which could fundamentally alter the landscape of modern medicine by enabling the body to repair itself at the cellular level.
See full Mogrify company page
